Veradermics, Incorporated (MANE)
NYSE: MANE · Real-Time Price · USD
138.78
+10.18 (7.92%)
At close: Nov 6, 2026, 4:00 PM EST
138.30
-0.48 (-0.35%)
After-hours: Nov 6, 2026, 7:48 PM EST
Veradermics Employees
Veradermics had 37 employees as of June 30, 2026. That makes Veradermics the 36,346th largest employer in the world and 4,979th in the United States.
Employees
37
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,818,649
Market Cap
5.80B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 37 | - | - |
| Mar 31, 2026 | 24 | - | - |
| Dec 31, 2025 | 21 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 470 |
| Immunovant | 315 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Kodiak Sciences | 141 |
MANE News
- 16 days ago - Veradermics price target raised to $204 from $170 at B. Riley - TheFly
- 19 days ago - Veradermics Transcript: Study result - Transcripts
- 19 days ago - Veradermics Press release: Study result - Filings
- 19 days ago - Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study - Reuters
- 19 days ago - Veradermics announces trial of VDPHL01 met primary, secondary endpoints - TheFly
- 19 days ago - Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304' Clinical Trial in Male Pattern Hair Loss - Business Wire
- 19 days ago - Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss - Business Wire
- 4 weeks ago - Veradermics rises 15.8% - TheFly